Antibiotic use and reduced effectiveness of second-line immunotherapy for lung cancer: all the time or just at the start of treatment?

E M W van de Garde; L R van Bedaf; D P Hurkmans; M M van den Heuvel

doi:10.1016/j.annonc.2020.09.007

Antibiotic use and reduced effectiveness of second-line immunotherapy for lung cancer: all the time or just at the start of treatment?

E M W van de Garde, L R van Bedaf, D P Hurkmans, M M van den Heuvel

Accenture Applied Intelligence NL, Amsterdam, The Netherlands.

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

Original language	English
Pages (from-to)	1779-1780
Number of pages	2
Journal	Annals of Oncology
Volume	31
Issue number	12
DOIs	https://doi.org/10.1016/j.annonc.2020.09.007
Publication status	Published - Dec 2020

Keywords

Anti-Bacterial Agents/therapeutic use
Antibodies, Monoclonal, Humanized
Carcinoma, Non-Small-Cell Lung
Humans
Immunotherapy
Lung Neoplasms/drug therapy
Proton Pump Inhibitors
Time

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.annonc.2020.09.007

PIIS0923753420424573Final published version, 188 KBLicence: Taverne

Cite this

@article{301e64f7485b444383dcf6eff56bbb4d,

title = "Antibiotic use and reduced effectiveness of second-line immunotherapy for lung cancer: all the time or just at the start of treatment?",

keywords = "Anti-Bacterial Agents/therapeutic use, Antibodies, Monoclonal, Humanized, Carcinoma, Non-Small-Cell Lung, Humans, Immunotherapy, Lung Neoplasms/drug therapy, Proton Pump Inhibitors, Time",

author = "{van de Garde}, {E M W} and {van Bedaf}, {L R} and Hurkmans, {D P} and {van den Heuvel}, {M M}",

year = "2020",

month = dec,

doi = "10.1016/j.annonc.2020.09.007",

language = "English",

volume = "31",

pages = "1779--1780",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Elsevier Ltd",

number = "12",

}

TY - JOUR

T1 - Antibiotic use and reduced effectiveness of second-line immunotherapy for lung cancer

T2 - all the time or just at the start of treatment?

AU - van de Garde, E M W

AU - van Bedaf, L R

AU - Hurkmans, D P

AU - van den Heuvel, M M

PY - 2020/12

Y1 - 2020/12

KW - Anti-Bacterial Agents/therapeutic use

KW - Antibodies, Monoclonal, Humanized

KW - Carcinoma, Non-Small-Cell Lung

KW - Humans

KW - Immunotherapy

KW - Lung Neoplasms/drug therapy

KW - Proton Pump Inhibitors

KW - Time

U2 - 10.1016/j.annonc.2020.09.007

DO - 10.1016/j.annonc.2020.09.007

M3 - Comment/Letter to the editor

C2 - 32976935

SN - 0923-7534

VL - 31

SP - 1779

EP - 1780

JO - Annals of Oncology

JF - Annals of Oncology

IS - 12

ER -